

1
2
3 1 **ANTIOXIDANT RESPONSES FOLLOWING ACTIVE AND PASSIVE SMOKING OF TOBACCO AND**
4
5 2 **ELECTRONIC CIGARETTES**
6
7
8 3

9
10 4 Konstantina Poulianiti^{1,2}, Christina Karatzaferi^{1,2}, Andreas D. Flouris^{1,2}, Ioannis G. Fatouros^{1,2}, Yiannis
11
12 5 Koutedakis^{1,2,3}, Athanasios Z. Jamurtas^{1,2}
13
14
15 6

16
17 7 ¹Department of Physical Education & Sport Science, University of Thessaly, Karies, Trikala 42100, Greece.

18
19 8 ²Institute of Research and Technology Thessaly, Centre for Research and Technology Hellas, Trikala,
20
21 9 Greece.
22

23
24 10 ³School of Sports, Performing Arts and Leisure, University of Wolverhampton, United Kingdom.
25
26
27 11

28
29 12 **CORRESPONDING AUTHOR:**

30
31 13 Athanasios Z. Jamurtas

32
33 14 Department of Physical Education & Sport Science

34
35 15 University of Thessaly

36
37 16 Karies, Trikala 42100, Greece, Tel: +30 24310 47054; Fax: +30 24310 47054

38
39 17 E-mail: ajamurt@pe.uth.gr
40
41
42 18
43
44 19
45
46

47 20 **Keywords:** oxidative stress; redox status; glutathione; secondhand smoke; free radicals.
48
49
50
51
52
53
54
55
56
57
58
59
60

21 **ABSTRACT**

22 **Context:** It has been indicated that acute active and passive tobacco cigarette smoking may cause
23 changes on redox status balance that may result in significant pathologies. However, no study has
24 evaluated the effects of active and passive e-cigarette smoking on redox status of consumers.

25 **Objective:** To examine the acute effects of active and passive e-cigarette and tobacco cigarette smoking
26 on selected redox status markers.

27 **Methods:** Using a randomized single-blind crossover design, 30 participants (15 smokers and 15 non-
28 smokers) were exposed to three different experimental conditions. Smokers underwent a control
29 session, an active tobacco cigarette smoking session (smoked 2 cigarettes within 30-min) and an active
30 e-cigarette smoking session (smoked a pre-determined number of puffs within 30-min using a liquid
31 with 11 ng/ml nicotine). Similarly, non- smokers underwent a control session, a passive tobacco
32 cigarette smoking session (exposure of 1 hour to 23 ± 1 ppm of CO in a 60 m^3 environmental chamber)
33 and a passive e-cigarette smoking session (exposure of 1 hour to air enriched with pre- determined
34 number of puffs in a 60 m^3 environmental chamber). Total antioxidant capacity (TAC), catalase activity
35 (CAT) and reduced glutathione (GSH) were assessed in participants' blood prior to, immediately after,
36 and 1-hour post-exposure. **Results:** TAC, CAT and GSH remained similar to baseline levels immediately
37 after and 1-hour-post exposure ($p>0.05$) in all trials. **Conclusions:** Tobacco and e-cigarette smoking
38 exposure do not acutely alter the response of the antioxidant system, neither under active nor passive
39 smoking conditions. Overall, there is not distinction between tobacco an e-cigarette active and passive
40 smoking effects on specific redox status indices.

41 INTRODUCTION

42 During the past decade, a new product has been introduced in the tobacco smoking substitutes market,
43 called electronic cigarette (e-cigarette) (Flouris and Oikonomou, 2010, Etter et al., 2011). The e-cigarette
44 is an electronic nicotine delivery device which consists of a rechargeable battery, an evaporator and
45 disposable filters (Flouris and Oikonomou, 2010, Etter et al., 2011). Due to lack of research on the safety
46 of e-cigarettes, the World Health Organization called for intensified research assessing the health effects
47 of e-cigarette use (World Health Organisation, 2010). Addressing this call, several studies have been
48 recently conducted on e-cigarettes. Some of these studies showed that the levels of tobacco-specific
49 toxicants in e-cigarette can be 9-450 times lower than in tobacco cigarette smoke (Goniewicz et al.,
50 2014), supporting the role of e-cigarettes in reducing harm from tobacco smoking. However, other
51 studies report that e-cigarette ‘vaping’ introduces new dangers. For example, it has been reported that a
52 high toxicity component, diethylene glycol, was detected in the liquid of e-cigarettes, albeit in
53 “approved” levels (Varlet et al., 2015). Additionally, substances like polycyclic aromatic hydrocarbons
54 and carcinogenic nitrosamines have been detected in some e-cigarette liquids (Pisinger and Dossing,
55 2014). Overall, the presence of such toxic agents appears to be brand-specific, as researchers examining
56 other brands found no traces of toxic or carcinogenic substances (Leondiadis, 2009). The above and
57 other conflicting reports have prompted calls for effective regulation and promotion of e-cigarette as
58 substitutes to tobacco smoking for existing smokers (Etter et al., 2011, Farsalinos and Le Houezec, 2015),
59 especially given the appeal of e-cigarettes to adolescents (Dutra and Glantz, 2014).

60 Oxidative stress reflects an imbalance between the systemic manifestation of free radicals and
61 the biological system’s ability to detoxify these reactive intermediates or to repair the resulting damage
62 (Sies and Cadenas, 1985). This redox imbalance may cause toxic effects that damage all components of
63 the cell including proteins, lipids and nucleic acids. Thus, oxidative stress is thought to be involved in the

1
2
3 64 development of several diseases such as cancer, cardiovascular disease, Parkinson's disease, Alzheimer's
4
5 65 disease and chronic fatigue syndrome (Sies and Cadenas, 1985). Reports indicate that **the acute and long**
6
7
8 66 **term (i.e., chronic) effects of active** and passive tobacco cigarette smoking may attenuate the
9
10 67 antioxidant defense system response which can, in turn, generate long-term pathologies (Valkonen and
11
12 68 Kuusi, 1998, Scheffler et al., 1992). **For example, increased lipid peroxidation and protein modification**
13
14 69 **due to smoking has been reported extensively in the literature when smokers were compared to non-**
15
16 70 **smokers (Pignatelli et al., 2001, Petruzzelli et al., 1997). Even though the exact mechanism that links**
17
18 71 **smoking with the development of atherosclerosis and damage to the vascular wall is still unclear,**
19
20 72 **evidence suggests that oxidants delivered by the tar and the gas phase become deposited in the lung**
21
22 73 **and also are delivered directly to the plasma and the vasculature and therefore activating enzymes**
23
24 74 **responsible for pro-oxidant development in the vascular wall (Heitzer et al., 2000). Furthermore,**
25
26 75 **damage to the vasculature can occur due to activation of neutrophils, monocytes, platelets, and T cells.**
27
28 76 **In addition, endothelial dysfunction that is present in active and passive smokers is augmented by the**
29
30 77 **antioxidant vitamin C, indicating that oxidative stress plays a crucial role in that phenomenon (Heitzer et**
31
32 78 **al., 2000).**

33
34
35
36
37
38 79 **Currently,** the effects of active and passive e-cigarette smoking on redox status remain
39
40 80 unknown. Evaluating the human redox status response to active and passive e-cigarette smoking may
41
42 81 aid in the understanding of oxidative stress contribution to the development of smoking-related
43
44 82 diseases. Therefore, the aim of this investigation was to examine the acute effects of active and passive
45
46 83 e-cigarette and tobacco cigarette smoking on selected redox status markers. Based on the
47
48 84 aforementioned findings that e-cigarettes may generate a reduced disruption in different body systems,
49
50 85 it was hypothesized that the acute effects of active and passive e-cigarette smoking on redox status
51
52 86 would be less pronounced as compared to active and passive tobacco cigarette smoking.
53
54
55
56
57
58
59
60

1
2
3 874
5 88 **MATERIALS AND METHODS**6
7
8 89 **Participants**

9
10 90 The experimental protocol was approved by the Ethics Committee of the Department of Physical
11
12 91 Education and Sports Science at the University of Thessaly. Two groups of **healthy** adult volunteers
13
14 92 participated and signed a written consent after being informed of all risks and benefits of the study. One
15
16 93 group consisted of 15 smokers (≥ 15 cigarettes / day; 8 men; 7 women; 36.8 ± 9.9 years; BMI 25.6 ± 4.1
17
18 94 kg/m^2) and another group consisted of 15 non-smokers (8 men; 7 women; 28.87 ± 10.5 years; BMI
19
20 95 $23.6 \pm 3.0 \text{ kg/m}^2$). Exclusion criteria included acute illness, cardiovascular diseases, intake of medication
21
22 96 or antioxidant supplements, pregnancy and previous use of e-cigarette by smokers. For non-smokers,
23
24 97 smoking was an additional exclusion criterion.
25
26
27
28
29

30
31 99 **Study Design and Procedures**

32
33 100 Participants **in each group (active smokers and passive non-smokers)** underwent three different
34
35 101 experimental sessions that were performed in a random order (separated by a minimum of seven days).
36
37 102 Participants were required to avoid food for 10 hours, strenuous physical activity for 72 hours and
38
39 103 smoking or exposure to smoke during the night prior to the measurements. This study was part of a
40
41 104 larger study and the procedures followed are described in detail elsewhere (Flouris et al., 2013).
42
43
44
45

46
47 106 **Active smokers**

48
49 107 Active smokers underwent a control session (AS_{CON}), an active tobacco cigarette smoking session (AS_{TOB})
50
51 108 and an active e- cigarette smoking session (AS_{E-CIG}). Blood samples were collected prior to, immediately
52
53 109 after, as well as one hour after the smoking sessions. During the AS_{CON} session, participants were asked
54
55
56
57
58
59
60

1
2
3 110 to draw puffs on a non-lit cigarette of their own brand, for 30 minutes. In the AS_{TOB} session participants
4
5 111 smoked two tobacco cigarettes of their own brand within 30 minutes. During the AS_{E-CIG} session,
6
7 112 participants smoked a certain number of puffs on an e-cigarette (device: GIANT, NOBACCO GP, Greece)
8
9 113 within 30 minutes. The e-cigarette liquid (NOBACCO USA MIX, NOBACCO GP, Greece) used, had tobacco
10
11 114 taste and contained 11 mg/ml nicotine. The specific e-cigarette and liquid was selected for the study due
12
13 115 to the fact that this liquid was the only one in Greece that had been previously analyzed by an
14
15 116 independent publicly-funded Research Institute and consisted of >60% propylene glycol, <10% nicotine,
16
17 117 <5% linalool, <5% tobacco essence and <1% methyl vanilyl (Leondiadis, 2009). A previously-developed
18
19 118 equation (Flouris et al., 2013) was used to calculate the number of e-cigarette puffs to ensure that the
20
21 119 amount of nicotine entering the human body would be equivalent to the amount of nicotine inhaled
22
23 120 when smoking a tobacco cigarette: $[(\text{mg of nicotine in own brand of tobacco cigarettes} \times 1.5 \times 50)/11] \times$
24
25 121 2.
26
27
28
29
30
31
32

33 *Passive non-smokers*

34
35 124 Non-smokers underwent a control session (PS_{CON}), a passive tobacco cigarette smoking session (PS_{TOB})
36
37 125 and a passive e-cigarette smoking session (PS_{E-CIG}). Blood samples were collected prior to, immediately
38
39 126 after, as well as one hour after the smoking sessions, as previously described (Flouris et al., 2013).
40
41 127 Briefly, in the PS_{CON} session, participants were asked to remain for 1 hour in a 60 m³ environmental
42
43 128 chamber (air temperature: 21°C; air velocity: 0.05 m/sec; humidity: 45%) while breathing normal air. In
44
45 129 the PS_{TOB} session, participants were exposed in the same chamber for 1 hour to air polluted with
46
47 130 tobacco cigarette smoke at a CO concentration of 23±1 ppm, *that is similar to the one at bar/restaurant*
48
49 131 *levels* (CO90 CO-CO₂ analyzer, Martindale Electric Ltd., Watford, UK). The required concentration of the
50
51
52 132 gas mixture was achieved by combustion of cigarettes from several popular brands using an air pump
53
54
55
56
57
58
59
60

1
2
3 133 (DYN, Volos, Greece), which regulated the airflow at 4 L/min. Cigarettes were half smoked using the air
4
5 134 pump, then they were left lit for 2 min to generate sidestream smoke, and then the rest of the cigarettes
6
7 135 were smoked via the air pump. An average of 29.2 ± 0.9 cigarettes was smoked in order to achieve the
8
9 136 required level of CO in the exposure chamber. In the PS_{E-CIG} session, participants were exposed to air
10
11 137 polluted with e-cigarette vapour for one hour in the same chamber. In this case, the air was polluted by
12
13 138 smoking e-cigarettes (device and liquid same as those used during the AS_{E-CIG} session) via the same air
14
15 139 pump set at an air flow rate of 4 L/min for the same time as in the PS_{TOB} session.
16
17
18
19
20

140

141 **Blood Collection and Handling**

142 Blood samples (5 ml) were collected from each antecubital vein and were placed into EDTA-containing
143 tubes (20 µl EDTA/ml of blood). In order to obtain plasma, samples were centrifuged immediately at
144 1,370 x g, at 4°C for 10 min. The supernatant plasma was collected, aliquoted in Eppendorf tubes, stored
145 at -80°C and thawed only once before analyzed for total antioxidant capacity (TAC). Red blood cells
146 lysate was produced by diluting packed erythrocytes with distilled water (1:1 vol:vol). The mixture was
147 inverted vigorously and centrifuged at 4,000 x g, at 4°C for 15 min. The supernatant was collected and
148 aliquoted in Eppendorf tubes, stored at -80°C and thawed only once before analyzed for reduced
149 glutathione (GSH) and catalase activity (CAT). Finally, in order to obtain serum, another portion of blood
150 sample (5 ml) was collected and placed into separate tubes containing clot activator, left for 20 min to
151 clot at room temperature, and centrifuged at 1,370 x g, at 4°C for 10 min. The supernatant was collected
152 and aliquoted in Eppendorf tubes, stored at -80°C and thawed only once before analyzed for cotinine.

153

154 **Assays**

1
2
3 155 Procedures used to assess cotinine levels in circulating blood are described elsewhere (Flouris et al.,
4
5 156 2013). Reduced glutathione concentration was determined using previous methodology (Reddy et al.,
6
7 157 2004). Briefly, 500 μ l of red blood cells lysate was treated with 500 μ l TCA 5%, centrifuged at 16000 x g,
8
9 158 at 4°C for 10 min. 300 μ l of the supernatant was collected and added in 90 μ l TCA 5%, centrifuged at
10
11 159 16000 x g, at 4°C for 10 min. Thereafter, 20 μ l of the TCA treated supernatant was mixed with 660 μ l of
12
13 160 67 mM sodium-potassium phosphate (pH 7.95) and 330 μ l of 1 mM 5,5'-Dithiobis (2-nitrobenzoic acid)
14
15 161 (DTNB). The samples were incubated in the dark at room temperature for 45 min and the absorbance
16
17 162 was read at 412 nm using a spectrophotometer. The GSH concentration was calculated by standard
18
19 163 curve constructed using commercially available standards.

20
21
22
23
24 164 Catalase activity was measured according to the Aebi assay (Aebi, 1984). Briefly, 4 μ l of red
25
26 165 blood cells lysate (diluted 1:10) were added to 2,991 μ l of 67 mM sodium-potassium phosphate buffer
27
28 166 (pH 7.4) and the samples were incubated at 37°C for 10 min. The sample was transferred into a glass
29
30 167 cuvette, 5 μ l of 30% hydrogen peroxide was added and the change in absorbance was immediately read
31
32 168 at 240 nm for 90 sec.

33
34
35 169 Total Antioxidant Capacity was determined according to Janaszewska & Bartosz assay
36
37 170 (Janaszewska and Bartosz, 2002), based on the scavenging of 2,2-diphenyl-1 picrylhydrazyl (DPPH) free
38
39 171 radical. DPPH stock solution (10mM) was prepared by dissolving 0.02g DPPH in 5ml of methanol and mix
40
41 172 in the stirrer. The working solution was obtained by diluting stock solution 100 times with methanol.
42
43 173 Afterwards, 20 μ l of plasma was mixed with 480 μ l of 10mM sodium-potassium phosphate (pH 7.4) and
44
45 174 500 μ l of 0.1 M working solution (DPPH). The samples were incubated in the dark for 30 min at room
46
47 175 temperature, centrifuged at 20,000 x g, at 25°C for 3 min. 900 μ l of the supernatant was transferred
48
49 176 into a clean plastic cuvette and the absorbance was read at 520 nm using a spectrophotometer. TAC is
50
51 177 presented as mM of DPPH reduced to 2,2-diphenyl-1 picrylhydrazine (DPPH:H).

1
2
3 178 Intra-assay correlation coefficient for GSH, CAT and TAC were 3.5%, 2.8% and 2.2%, respectively.
4
5

6 179
7

8 180 **Statistical Analysis**

9
10 181 Based on data from a previously-published study (Flouris, 2009), the resulting minimum required sample
11
12 182 size for this study was eight participants per group, providing a reliability rate of 95%. To reduce the
13
14 183 probability of making a type II error, 15 participants were recruited for each group (smokers and non-
15
16 184 smokers). Normality was assessed by the Kolmogorov–Smirnov test and the distribution of all variables
17
18 185 was not found significantly different from normal. A two-way (trial × time) ANOVA with repeated
19
20 186 measures of time was used to assess differences between the three conditions in smokers and non-
21
22 187 smokers. Furthermore, a two way (condition x time) ANOVA was used to assess differences between the
23
24 188 passive and active condition. The level of statistical significance was set at $p < 0.05$. Data are presented as
25
26 189 mean ± SD. The SPSS version 15.0 (SPSS Inc., USA) was used for all analyses.
27
28
29
30

31 190
32

33 191 **RESULTS**

34 192 **Active Smoking**

35
36 193 No changes were observed in GSH (Figure 2A), CAT (Figure 3A), and TAC (Figure 4A) concentrations prior
37
38 194 to, immediately after and 1-hour after the exposure to AS_{TOB}, AS_{E-CIG} and AS_{CON} ($p > 0.05$). Furthermore, no
39
40 195 interaction between the three conditions was revealed for any time point of assessment in any of the
41
42 196 three variables (GSH, CAT, TAC) assessed ($p > 0.05$). Specifically, GSH ($\mu\text{mol/g Hb}$) levels for AS_{TOB} were
43
44 197 2.21 ± 0.85 prior to, 2.11 ± 0.76 immediately after, and 1.72 ± 0.82 one hour after the smoking sessions,
45
46 198 respectively. During AS_{E-CIG}, GSH levels were 2.07 ± 1.25 prior to, 2.17 ± 0.87 immediately after, and
47
48 199 2.26 ± 0.86 one hour after the smoking sessions, respectively. Finally, GSH levels for AS_{CON} were 1.65 ± 0.87
49
50 200 prior to, 1.80 ± 1.06 immediately after, and 1.92 ± 1.28 one hour after the smoking sessions, respectively.
51
52
53
54
55
56
57
58
59
60

1
2
3 201 CAT ($\mu\text{mol}/\text{min}/\text{mg Hb}$) activity for AS_{TOB} was 347 ± 33 prior to, 332 ± 14 immediately after, and 389 ± 43
4
5 202 one hour after the smoking sessions, respectively. Also, CAT activity for $AS_{\text{E-CIG}}$ was 357 ± 14 prior to,
6
7 203 331 ± 55 immediately after, and 354 ± 29 one hour after the smoking sessions, respectively. Finally, CAT
8
9 204 activity for AS_{CON} was 338 ± 53 prior to, 349 ± 66 immediately after, and 329 ± 51 one hour after the
10
11 205 smoking sessions, respectively. TAC (mM DPPH) levels for AS_{TOB} were 1.03 ± 0.09 prior to, 1.01 ± 0.09
12
13 206 immediately after and 0.99 ± 0.09 one hour after the smoking sessions, respectively. During $AS_{\text{E-CIG}}$, TAC
14
15 207 levels were 0.98 ± 0.14 prior to, 0.96 ± 0.11 immediately after, and 0.95 ± 0.12 one hour after the smoking
16
17 208 sessions, respectively. Finally, TAC levels for AS_{CON} were 1.04 ± 0.08 prior to, 1.00 ± 0.10 immediately after,
18
19 209 and 1.01 ± 0.09 one hour after the smoking sessions, respectively.
20
21
22
23
24
25
26
27

211 **Passive Smoking**

28 212 No time-dependent changes were found in GSH (Figure 2B), CAT (Figure 3B), and TAC (Figure 4B)
29
30 213 concentration prior to, immediately after and one hour after the exposure to PS_{TOB} , $PS_{\text{E-CIG}}$ and PS_{CON}
31
32 214 ($p>0.05$). No interaction between the three conditions was revealed for any time point of assessment in
33
34 215 any of the three variables (GSH, CAT, TAC) assessed ($p>0.05$). Specifically, GSH ($\mu\text{mol}/\text{g Hb}$) levels for
35
36 216 PS_{TOB} were 2.08 ± 1.02 prior to, 1.65 ± 0.66 immediately after, and 1.53 ± 0.81 one hour after the smoking
37
38 217 sessions, respectively. During $PS_{\text{E-CIG}}$ GSH levels were 2.35 ± 1.20 prior to, 2.65 ± 0.81 immediately after,
39
40 218 and 2.78 ± 1.18 one hour after the smoking sessions, respectively. Finally, GSH levels for PS_{CON} were
41
42 219 1.68 ± 0.85 prior to, 1.42 ± 0.97 immediately after, and 1.51 ± 0.94 one hour after the smoking sessions,
43
44 220 respectively. CAT ($\mu\text{mol}/\text{min}/\text{mgHb}$) activity for PS_{TOB} was 385 ± 53 prior to, 382 ± 45 immediately after,
45
46 221 and 377 ± 41 one hour after the smoking sessions, respectively. Also, CAT activity for $PS_{\text{E-CIG}}$ was 331 ± 60
47
48 222 prior to, 326 ± 50 immediately after, and 354 ± 72 one hour after the smoking sessions, respectively.
49
50 223 Finally, CAT activity for PS_{CON} was 357 ± 90 prior to, 330 ± 56 immediately after, and 327 ± 60 one hour after
51
52
53
54
55
56
57
58
59
60

1
2
3 224 the smoking sessions, respectively. TAC (mM DPPH) levels for PS_{TOB} were 1.03±0.16 prior to, 1.04±0.17
4
5 225 immediately after and 1.02±0.16 one hour after the smoking sessions, respectively. During PS_{E-CIG}, TAC
6
7 226 levels were 1.03±0.16 prior to, 1.06±0.18 immediately after, and 1.04±0.13 one hour after the smoking
8
9 227 sessions, respectively. Finally, TAC levels for PS_{CON} were 1.00±0.18 prior to, 0.97±0.14 immediately after,
10
11 228 and 0.99±0.17 one hour after the smoking sessions, respectively.
12
13
14
15 229

17 230 DISCUSSION

18
19 231 To our knowledge, this is the first study to examine the acute effects of active and passive e-cigarette
20
21 232 smoking on the antioxidant response in human blood. The results indicate that active and passive
22
23 233 smoking of e-cigarettes and tobacco cigarettes does not result in immediately visible perturbations of
24
25 234 the blood antioxidant system as evaluated by GSH, CAT and TAC.
26
27
28
29 235

30 31 236 Active Smoking

32
33 237 Previous research indicates that active smoking may have detrimental effects on human health (Flouris
34
35 238 et al., 2010). Tobacco smoking accounts for the largest amount of deaths and disability years in high-
36
37 239 income countries and is the third leading cause of death and disabilities in developing countries (Lopez
38
39 240 et al., 2006). Tobacco contains several substances that may influence the human physiology and has
40
41 241 been linked to oxidative stress development (Halliwell and Poulsen, 2006). Since the number of deaths is
42
43 242 mounting and the economic burden is escalating in the recent years, new products have been
44
45 243 introduced in the market to counteract the negative effects of smoking. Electronic cigarette is one of
46
47 244 them and some studies indicate that cotinine levels are similar to the one found after tobacco smoking
48
49
50 245 (Flouris et al., 2013).
51
52
53
54
55
56
57
58
59
60

1
2
3 246 Smoking either e-cigarettes or conventional tobacco cigarettes may disrupt human health. A
4
5
6 247 recent *in vitro* study showed that tobacco and e-cigarette products may initiate an inflammatory
7
8 248 response and oxidative stress production in Kupffer cells in the liver (Rubenstein et al., 2015).
9
10 249 Furthermore, short-term e-cigarette “vaping” generates smaller changes in lung function compared to
11
12 250 tobacco cigarette smoking (Flouris et al., 2013, Vardavas et al., 2011). However, inhaling an e-cigarette
13
14
15 251 for 5 min results in attenuated exhaled nitric oxide levels (Vardavas et al., 2011, Marini et al., 2014).
16
17 252 Changes in peripheral flow resistance due to acute narrowing of the diameter of the peripheral
18
19 253 pathways and lower levels of nitric oxide have been proposed as possible mechanisms for the changes in
20
21 254 exhaled nitric oxide levels following either tobacco or e-cigarette smoking (Vardavas et al., 2011). Nitric
22
23
24 255 oxide, besides having an important role in several physiological processes of the respiratory tract, has
25
26 256 been used as a marker for assessing oxidative stress (Hoyt et al., 2003).

27
28
29 257 In the literature, several studies have assessed the antioxidant status of healthy smokers.
30
31 258 According to Moriarty et al (Moriarty et al., 2003) a significant decrease in GSH levels in plasma of
32
33 259 smokers compared to non smokers, was found. However, regarding the activities of three of the most
34
35 260 significant antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx) and CAT,
36
37 261 contradictory results were found. Another study (Zhou et al., 2000) observed decreased activity of
38
39 262 these enzymes in erythrocytes of smokers compared to non smokers. Yildiz et al (Yildiz et al., 2002),
40
41 263 found decreased CAT and SOD activities, however, GPx activity remained unchanged in erythrocytes of
42
43 264 smokers compared to non smokers, On the other hand, increased activities of these enzymes were
44
45 265 observed in the erythrocytes of young smokers compared to age-matched non smokers (Ozguner et al.,
46
47 266 2005), reflecting that the small duration of smoking perhaps was not efficient to alter their enzymatic
48
49 267 antioxidant response. Finally, Meta et al (Metta et al., 2015), assessed the erythrocyte antioxidant
50
51 268 defense against cigarette smoking, finding that there was highly significant difference in SOD activity, in
52
53
54
55
56
57
58
59
60

1
2
3 269 comparison to CAT and GPx between smokers and non smokers. Indeed, while CAT and GPx activities
4
5 270 were found decreased, SOD activity was found increased in smokers compared to non smokers. TAC was
6
7
8 271 also assessed in blood of smokers and non smokers and was found unchanged in the study of Kurku et al
9
10 272 (Kurku et al., 2015) and decreased in smokers in the study of Mojtaba et al (Mojtaba et al., 2014)

11
12 273 In the study of Kurku et al (Kurku et al., 2015) acute effects of smoking on antioxidant defense
13
14 274 were also assessed. Specifically, saliva samples were collected from smokers 1 h after smoking only one
15
16
17 275 cigarette. Nevertheless, no difference in the levels of TAC, SOD and GPx was observed pre and before
18
19 276 smoking. The short period of exposure to only one cigarette, was not enough to cause antioxidant
20
21 277 defense modifications. The aforementioned attenuation of exhaled nitric oxide levels following active e-
22
23
24 278 cigarette and tobacco cigarette smoking may suggest changes in redox status. However, we did not
25
26 279 observe any statistically significant acute changes in antioxidant levels either in time or between groups.
27
28
29 280 We scrutinized our data further by examining our data as percentage of initial value, to account for
30
31 281 subject variability (data not shown) without again finding statistically significant alterations in
32
33 282 antioxidant levels. Perhaps the oxidative stress does not stem from a reduction in antioxidant capacity
34
35 283 but from an increase in oxidants. Moreover, the tissue assessed may play a role. In this study we
36
37
38 284 assessed changes in the antioxidant system in blood and red blood cells lysate (to systemic oxidative
39
40 285 status) whereas the exhaled nitric oxide levels assessed in previous studies indicates airway oxidative
41
42 286 stress. Additionally, we restricted our study to the immediate effects of smoking on antioxidant levels.
43
44
45 287 Therefore, we cannot exclude that reductions in antioxidant capacity could be revealed if sampling was
46
47 288 repeated some hours after the exposure. Further studies are needed to elucidate possible differences in
48
49 289 the redox response between tissues, especially following active e-cigarette smoking.

50
51
52 290

53
54 291 **Passive Smoking**

1
2
3 292 Chronic exposure to passive tobacco smoking has been shown to generate unfavourable health effects
4
5 293 (Faught et al., 2009, Carrillo et al., 2009) since it increases the risk of heart disease by approximately
6
7 294 30% whereas acute exposure (minutes to hours) has nearly as large effects as chronic active smoking
8
9
10 295 (Metsios et al., 2007, Dinas et al., 2011, Barnoya and Glantz, 2005). The negative health effects of
11
12 296 tobacco passive smoking are exemplified by acute unfavorable effects on lung function, cytokine
13
14 297 production, thyroid hormone secretion, and complete blood count parameters (Dinas et al., 2014,
15
16 298 Flouris et al., 2008, Metsios et al., 2007). Chronic exposure to passive tobacco smoking has been also
17
18 299 shown to result in changes in redox balance. Exposure to chronic passive smoking results in a 63%
19
20 300 increase in 8-hydroxy-2'-deoxyguanosine in the blood of exposed subjects and 13% and 37% increase in
21
22 301 catalase and glutathione peroxidase activity, respectively (Howard et al., 1998). Furthermore, a strong
23
24 302 association between serum protein carbonyl and malondialdehyde concentration has been revealed in
25
26 303 non-smoker patients hospitalized for acute myocardial infarction (Megson et al., 2013). Yildiz et al (Yildiz
27
28 304 et al., 2002), evaluated the erythrocyte antioxidant defence of passive smokers and found significantly
29
30 305 decreased CAT and SOD activities in passive smokers in comparison to non smokers. Based on these
31
32 306 findings, it is clear that exposure of chronic passive tobacco smoking can lead to changes in redox status.
33
34 307 However, there is only a limited number of interventional studies that assessed oxidative stress
35
36 308 responses following a single exposure to passive smoking. These studies indicate that acute passive
37
38 309 tobacco smoking results in airway acidification, oxidative stress, and decreased levels of FeNO (Flouris et
39
40 310 al., 2013, Kostikas et al., 2013). Furthermore, significant increases have been reported in 8-isoprostane
41
42 311 levels after 30 min of passive smoking, an increase that was equivalently to the levels of smokers (Kato
43
44 312 et al., 2006). These results are in contrast with the current findings of no changes in redox status
45
46 313 markers neither immediately post nor 1-hour post exposure. Possible reasons for this contradiction
47
48 314 might be that we assessed components of the antioxidant system whereas the previous studies assessed
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 315 markers of oxidative stress. Furthermore, two of the three aforementioned studies assessed oxidative
4
5 316 stress in lungs. We assessed systemic oxidative stress in molecules found in the blood which may not
6
7
8 317 reflect lung tissue levels, or may require some time before any changes are observed.
9

10 318 Acute exposure to passive e-cigarette environments has been shown to increase cotinine levels
11
12 319 to an extent similar to that of passive tobacco cigarette smoking (Flouris et al., 2013). However, passive
13
14 320 e-cigarette vapour exposure shows no significant changes in lung function (Flouris et al., 2013).
15
16
17 321 Furthermore, passive e-cigarette vapour exposure does not appear to influence the results of the
18
19 322 complete blood count examination (Flouris et al., 2012). The present results indicate that a 1-hour
20
21 323 exposure to a passive e-cigarette environment does not cause significant perturbations in the
22
23 324 antioxidant system up to 1-hour post-exposure. It is possible that changes would become evident if we
24
25 325 had continued our observation for a longer period. Finally, as our measurements indicate systemic redox
26
27 326 status, we cannot exclude alterations at the level of the lung epithelial cells, as observed in a mouse
28
29 327 study (Lerner et al., 2015).
30
31

32
33 328 It is important to note that, while we instructed our subjects to consume similar meals in the
34
35 329 day prior to each assessment, we did not strictly monitor their diet. High levels of food and/or high
36
37 330 activity of other endogenous antioxidants may explain the lack of responses in the antioxidant system
38
39 331 following the active or passive smoking procedures. This is because the bioavailability of the antioxidant
40
41 332 vitamin C changes following smoking whereas its turnover in smokers is 40% higher compared to non-
42
43 333 smokers (German Nutrition, 2015).
44
45
46
47
48

49 335 **CONCLUSION**

50
51
52 336 In conclusion, we found that tobacco and e-cigarette smoking exposure do not acutely alter the
53
54 337 response of the antioxidant system, neither under active nor passive smoking conditions. Overall, there
55
56
57
58
59
60

1
2
3 338 is not distinction between tobacco and e-cigarette active and passive smoking effects on specific redox
4
5 339 status indices.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

340 REFERENCES

- 341 AEBI, H. 1984. Catalase in vitro. *Methods Enzymol*, 105, 121-6.
- 342 BARNOYA, J. & GLANTZ, S. A. 2005. Cardiovascular effects of secondhand smoke: nearly as large as
343 smoking. *Circulation*, 111, 2684-98.
- 344 CARRILLO, A. E., METSIOS, G. S. & FLOURIS, A. D. 2009. Effects of secondhand smoke on thyroid
345 function. *Inflamm Allergy Drug Targets*, 8.
- 346 DINAS, P. C., KOUTEDAKIS, Y. & FLOURIS, A. D. 2011. Effects of active and passive tobacco cigarette
347 smoking on heart rate variability. *Int J Cardiol*, 163, 109-115.
- 348 DINAS, P. C., METSIOS, G. S., JAMURTAS, A. Z., TZATZARAKIS, M. N., WALLACE HAYES, A., KOUTEDAKIS,
349 Y., TSATSAKIS, A. M. & FLOURIS, A. D. 2014. Acute effects of second-hand smoke on complete
350 blood count. *Int J Environ Health Res*, 24, 56-62.
- 351 DUTRA, L. M. & GLANTZ, S. A. 2014. Electronic cigarettes and conventional cigarette use among U.S.
352 adolescents: a cross-sectional study. *JAMA Pediatr*, 168, 610-7.
- 353 ETTER, J. F., BULLEN, C., FLOURIS, A. D., LAUGESEN, M. & EISSENBERG, T. 2011. Electronic nicotine
354 delivery systems: a research agenda. *Tob Control*, 20, 243-8.
- 355 FARSALINOS, K. E. & LE HOUEZEC, J. 2015. Regulation in the face of uncertainty: the evidence on
356 electronic nicotine delivery systems (e-cigarettes). *Risk Manag Healthc Policy*, 8, 157-67.
- 357 FAUGHT, B. E., FLOURIS, A. D. & CAIRNEY, J. 2009. Epidemiological evidence associating secondhand
358 smoke exposure with cardiovascular disease. *Inflamm Allergy Drug Targets*, 8.
- 359 FLOURIS, A. D., CHORTI, M. S., POULIANITI, K. P., JAMURTAS, A. Z., KOSTIKAS, K., TZATZARAKIS, M. N.,
360 WALLACE HAYES, A., TSATSAKIS, A. M. & KOUTEDAKIS, Y. 2013. Acute impact of active and
361 passive electronic cigarette smoking on serum cotinine and lung function. *Inhal Toxicol*, 25, 91-
362 101.
- 363 FLOURIS, A. D., METSIOS, G. S., JAMURTAS, A. Z. & KOUTEDAKIS, Y. 2008. Sexual dimorphism in the
364 acute effects of secondhand smoke on thyroid hormone secretion, inflammatory markers and
365 vascular function. *Am J Physiol Endocrinol Metab*, 294, E456-62.
- 366 FLOURIS, A. D., METSIOS, G. S., JAMURTAS, A. Z. & KOUTEDAKIS, Y. 2010. Cardiorespiratory and immune
367 response to physical activity following exposure to a typical smoking environment. *Heart*, 96,
368 860-4.
- 369 FLOURIS, A. D. & OIKONOMOU, D. N. 2010. Electronic cigarettes: miracle or menace? *BMJ*, 340, c311.
- 370 FLOURIS, A. D., POULIANITI, K. P., CHORTI, M. S., JAMURTAS, A. Z., KOURETAS, D., OWOLABI, E. O.,
371 TZATZARAKIS, M. N., TSATSAKIS, A. M. & KOUTEDAKIS, Y. 2012. Acute effects of electronic and
372 tobacco cigarette smoking on complete blood count. *Food Chem Toxicol*, 50, 3600-3603.
- 373 GERMAN NUTRITION, S. 2015. New Reference Values for Vitamin C Intake. *Ann Nutr Metab*, 67, 13-20.
- 374 GONIEWICZ, M. L., KNYSAK, J., GAWRON, M., KOSMIDER, L., SOBCZAK, A., KUREK, J., PROKOPOWICZ, A.,
375 JABLONSKA-CZAPLA, M., ROSIK-DULEWSKA, C., HAVEL, C., JACOB, P., 3RD & BENOWITZ, N. 2014.
376 Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control*,
377 23, 133-9.
- 378 HALLIWELL, B. B. & POULSEN, H. E. 2006. *Cigarette smoke and oxidative stress*, Berlin, Germany,
379 Springer-Verlag.
- 380 HEITZER, T., BROCKHOFF, C., MAYER, B., WARNHOLTZ, A., MOLLNAU, H., HENNE, S., MEINERTZ, T. &
381 MUNZEL, T. 2000. Tetrahydrobiopterin improves endothelium-dependent vasodilation in
382 chronic smokers : evidence for a dysfunctional nitric oxide synthase. *Circ Res*, 86, E36-41.

- 1
2
3 383 HOWARD, D. J., BRIGGS, L. A. & PRITSOS, C. A. 1998. Oxidative DNA damage in mouse heart, liver, and
4 384 lung tissue due to acute side-stream tobacco smoke exposure. *Arch Biochem Biophys*, 352, 293-
5 385 7.
6
7 386 HOYT, J. C., ROBBINS, R. A., HABIB, M., SPRINGALL, D. R., BUTTERY, L. D., POLAK, J. M. & BARNES, P. J.
8 387 2003. Cigarette smoke decreases inducible nitric oxide synthase in lung epithelial cells. *Exp Lung*
9 388 *Res*, 29, 17-28.
10 389 JANASZEWSKA, A. & BARTOSZ, G. 2002. Assay of total antioxidant capacity: comparison of four methods
11 390 as applied to human blood plasma. *Scand J Clin Lab Invest*, 62, 231-6.
12 391 KATO, T., INOUE, T., MOROOKA, T., YOSHIMOTO, N. & NODE, K. 2006. Short-term passive smoking
13 392 causes endothelial dysfunction via oxidative stress in nonsmokers. *Can J Physiol Pharmacol*, 84,
14 393 523-9.
15
16 394 KOSTIKAS, K., MINAS, M., NIKOLAOU, E., PAPAIOANNOU, A. I., LIAKOS, P., GOUGOURA, S.,
17 395 GOURGOULIANIS, K. I., DINAS, P. C., METSIOS, G. S., JAMURTAS, A. Z., FLOURIS, A. D. &
18 396 KOUTEDAKIS, Y. 2013. Secondhand smoke exposure induces acutely airway acidification and
19 397 oxidative stress. *Respir Med*, 107, 172-9.
20
21 398 KURKU, H., KACMAZ, M., KISA, U., DOGAN, O. & CAGLAYAN, O. 2015. Acute and chronic impact of
22 399 smoking on salivary and serum total antioxidant capacity. *J Pak Med Assoc*, 65, 164-9.
23 400 LEONDIADIS, L. 2009. *Results of chemical analyses in NOBACCO electronic cigarette refills* [Online].
24 401 Athens, Greece: Mass Spectrometry and Dioxin Analysis Lab, National Center for Scientific
25 402 Research "Demokritos". Available: <http://www.nobacco.gr/datafiles/files/DIMOKRITOS.pdf>
26 403 [Accessed October 19 2009].
27
28 404 LERNER, C. A., SUNDAR, I. K., YAO, H., GERLOFF, J., OSSIP, D. J., MCINTOSH, S., ROBINSON, R. &
29 405 RAHMAN, I. 2015. Vapors produced by electronic cigarettes and e-juices with flavorings induce
30 406 toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung.
31 407 *PLoS One*, 10, e0116732.
32 408 LOPEZ, A. D., MATHERS, C. D., EZZATI, M., JAMISON, D. T. & MURRAY, C. J. L. 2006. *Global burden of*
33 409 *disease and risk factors*, New York, USA, The World Bank and Oxford University Press.
34 410 MARINI, S., BUONANNO, G., STABILE, L. & FICCO, G. 2014. Short-term effects of electronic and tobacco
35 411 cigarettes on exhaled nitric oxide. *Toxicol Appl Pharmacol*, 278, 9-15.
36
37 412 MEGSON, I. L., HAW, S. J., NEWBY, D. E. & PELL, J. P. 2013. Association between exposure to
38 413 environmental tobacco smoke and biomarkers of oxidative stress among patients hospitalised
39 414 with acute myocardial infarction. *PLoS One*, 8, e81209.
40 415 METSIOS, G. S., FLOURIS, A. D., JAMURTAS, A. Z., CARRILLO, A. E., KOURETAS, D., GERMENIS, A. E.,
41 416 GOURGOULIANIS, K., KIROPOULOS, T., TZATZARAKIS, M. N., TSATSAKIS, A. M. & KOUTEDAKIS, Y.
42 417 2007. A brief exposure to moderate passive smoke increases metabolism and thyroid hormone
43 418 secretion. *J Clin Endocrinol Metab*, 92, 208-11.
44
45 419 METTA, S., BASALINGAPPA, D. R., UPPALA, S. & MITTA, G. 2015. Erythrocyte Antioxidant Defenses
46 420 Against Cigarette Smoking in Ischemic Heart Disease. *J Clin Diagn Res*, 9, BC08-11.
47 421 MOJTABA, W., DAVOOD, K. & HUSSEIN, D. 2014. Lower Total Antioxidant Capacity in Smokers Compare
48 422 to
49
50 423 Non-smokers. *Biological Forum – An International Journal*, 6, 305-309.
51 424 MORIARTY, S. E., SHAH, J. H., LYNN, M., JIANG, S., OPENO, K., JONES, D. P. & STERNBERG, P. 2003.
52 425 Oxidation of glutathione and cysteine in human plasma associated with smoking. *Free Radic Biol*
53 426 *Med*, 35, 1582-8.
54
55
56
57
58
59
60

- 1
2
3 427 OZGUNER, F., KOYU, A. & CESUR, G. 2005. Active smoking causes oxidative stress and decreases blood
4 428 melatonin levels. *Toxicol Ind Health*, 21, 21-6.
- 5 429 PETRUZZELLI, S., PUNTONI, R., MIMOTTI, P., PULERA, N., BALIVA, F., FORNAI, E. & GIUNTINI, C. 1997.
6 430 Plasma 3-nitrotyrosine in cigarette smokers. *Am J Respir Crit Care Med*, 156, 1902-7.
- 7 431 PIGNATELLI, B., LI, C. Q., BOFFETTA, P., CHEN, Q., AHRENS, W., NYBERG, F., MUKERIA, A., BRUSKE-
8 432 HOHLFELD, I., FORTES, C., CONSTANTINESCU, V., ISCHIROPOULOS, H. & OHSHIMA, H. 2001.
9 433 Nitrated and oxidized plasma proteins in smokers and lung cancer patients. *Cancer Res*, 61, 778-
10 434 84.
- 11 435 PISINGER, C. & DOSSING, M. 2014. A systematic review of health effects of electronic cigarettes. *Prev*
12 436 *Med*, 69, 248-60.
- 13 437 REDDY, Y. N., MURTHY, S. V., KRISHNA, D. R. & PRABHAKAR, M. C. 2004. Role of free radicals and
14 438 antioxidants in tuberculosis patients. *Ind J Tuberculosis*, 51, 213-218.
- 15 439 RUBENSTEIN, D. A., HOM, S., GHEBREHIWET, B. & YIN, W. 2015. Tobacco and e-cigarette products
16 440 initiate Kupffer cell inflammatory responses. *Mol Immunol*, 67, 652-60.
- 17 441 SCHEFFLER, E., WIEST, E., WOEHRLE, J., OTTO, I., SCHULZ, I., HUBER, L., ZIEGLER, R. & DRESEL, H. A. 1992.
18 442 Smoking influences the atherogenic potential of low-density lipoprotein. *Clin Investig*, 70, 263-8.
- 19 443 SIES, H. & CADENAS, E. 1985. Oxidative stress: damage to intact cells and organs. *Philos Trans R Soc Lond*
20 444 *B Biol Sci*, 311, 617-31.
- 21 445 VALKONEN, M. & KUUSI, T. 1998. Passive smoking induces atherogenic changes in low-density
22 446 lipoprotein. *Circulation*, 97, 2012-6.
- 23 447 VARDAVAS, C. I., ANAGNOSTOPOULOS, N., KOUGIAS, M., EVANGELOPOULOU, V., CONNOLLY, G. N. &
24 448 BEHRAKIS, P. K. 2011. Acute pulmonary effects of using an e-cigarette: impact on respiratory
25 449 flow resistance, impedance and exhaled nitric oxide. *Chest*.
- 26 450 VARLET, V., FARSALINOS, K., AUGSBURGER, M., THOMAS, A. & ETTER, J. F. 2015. Toxicity assessment of
27 451 refill liquids for electronic cigarettes. *Int J Environ Res Public Health*, 12, 4796-815.
- 28 452 WORLD HEALTH ORGANISATION 2010. WHO Regulatory Consultation on the Safety of Electronic
29 453 Nicotine Delivery Devices (ENDS). Geneva: World Health Organisation.
- 30 454 YILDIZ, L., KAYAOGLU, N. & AKSOY, H. 2002. The changes of superoxide dismutase, catalase and
31 455 glutathione peroxidase activities in erythrocytes of active and passive smokers. *Clin Chem Lab*
32 456 *Med*, 40, 612-5.
- 33 457 ZHOU, J. F., YAN, X. F., GUO, F. Z., SUN, N. Y., QIAN, Z. J. & DING, D. Y. 2000. Effects of cigarette smoking
34 458 and smoking cessation on plasma constituents and enzyme activities related to oxidative stress.
35 459 *Biomed Environ Sci*, 13, 44-55.

460

1
2
3 461 **LIST OF FIGURES**
4

5 462 **Figure 1.** Electronic cigarette components.
6
7

8 463
9


10 464 **Figure 2.** Glutathione (GSH) levels (mean±SD) following active (A) and passive smoking (B).
11

12 465
13

14 466 **Figure 3** Catalase activity (mean±SD) following active (A) and passive smoking (B).
15
16



17 467
18



19 468 **Figure 4.** Total antioxidant activity (TAC) levels (mean±SD) following active (A) and passive smoking (B).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

